Aminophylline, Cardiac Surgical Procedures, Diuretic Effect, Furosemide
Conditions
Brief summary
This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.
Detailed description
Acute Kidney injury (AKI) is a serious and common complication after either adult or pediatric cardiac surgery. The results of a recent meta-analysis suggested that loop diuretics (furosemide) may reduce postoperative creatinine clearance, whereas aldosterone agonists (spironolactone) increase the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI). Diuretics are not recommended for the prevention of AKI, but loop diuretics may be used for the management of volume overload Aminophylline in cardiac surgery can reduce the frequency of AKI and could be used in the prevention of AKI as a safe and efficient modality in high-risk patients.
Interventions
DRUGAminophylline
Patients will receive Aminophylline.
DRUGFurosemide
Patients will receive furosemide.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18-65 years. * Both sexes. * All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.). * Body mass index (BMI) ranged between 20 and 40 kg/m2.
Exclusion criteria
* Sensitivity or contraindication to Aminophylline or furosemide * Stage-5 chronic kidney disease (CKD) \[Glomerular filtration rate (GFR) of less than 15 mL/min\]. * The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease. * Recipients of dialysis before surgery. * Recipients of solid-organ transplantation before surgery. * Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc). * Patient refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of urine output | Two hours after cardiopulmonary bypass | Urine output will be measured at two hours after cardiopulmonary bypass. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) | 48 hours after cardiopulmonary bypass | Estimated Glomerular Filtration Rate (eGFR) at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB. |
| Measurement of fluid balance | 48 hours after cardiopulmonary bypass | Fluid balance at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB. |
| Urea level | 48 hours after cardiopulmonary bypass | Urea level will be measured at 8 hours and 48 hours after cardiopulmonary bypass. |
| Creatinine level | 48 hours after cardiopulmonary bypass | Creatinine level will be measured at 8 hours and 48 hours after cardiopulmonary bypass. |
| Lactate level | 48 hours after cardiopulmonary bypass | Lactate level will be measured at 8 hours and 48 hours after cardiopulmonary bypass. |
| Measurement of urine output at completion of cardiopulmonary bypass | 48 hours after cardiopulmonary bypass | Urine output at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB. |
Countries
Egypt
Contacts
CONTACTAhmed M Hassan, MSc
Outcome results
None listed